10 year montly chart. Theralase preparing for range breakout TLTFF Dipped out of its 10-year range due to Covid and an initial Phase 2 Protocall that was corrected after the first 12 patients. The first 12 treated patients from the phase 2 study were very substantially undertreated, in both 1433 instill volume and bladder volume calculations. That had to be corrected after the first "dirty dozen" were treated. The company corrected the issue, and we are now seeing the good data just start to come in. That is why we are entering back into the 10-year range.
The patients from previously completed the phase 1 study only received one treatment. In this phase 2 PIVITOL study the patients will receive 2 treatments. The second treatment any dirty dozen patients get would have been or will be at the highly effective dose. (2nd treatment is scheduled 6 months from first treatment.)
The initial assessment of the Phase 1 study was so good it was halted early for the starting of the Phase 2 study.
Covid delays also like the whole broader markets affected this stock. But they have been treating patients and are in progress with Data for Breakthrough Thearapy Designation. BTD Theralase was especially hit hard by the covid circumstance.
We are back in the low side of the range with more significant developments than ever before in the stocks history.
If this stock shows stability at around .32 CAD (.25 cents USD) till the next release and the data is good again I think the probability of getting to the high range or a breakout is probable.
Selling Cheap is silly....
The science is solid.
Cheers,
Float
Long TLTFF since 2014